Protara Therapeutics is trading 6.98% up at $3.75 after rising from the September 21 close of $3.51; no clear company-specific catalyst has been identified.
- Fresh coverage reports $142 million in cash, no debt, and approximately 2.1 years of runway.
- The coverage does not link those figures to today’s rally.
- Broader markets are mixed, offering limited confirmation.